New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
10:15 EDTKMI, CZR, ACT, EBAY, KKR, APC, DG, WMB, ADT, GMLeon Cooperman gives quarterly update on stakes
NEW STAKES: Dollar General (DG)... Actavis (ACT)... ADT Corp. (ADT)... Anadarko (APC). INCREASED STAKES: Caesar's (CZR)... eBay (EBAY)... Sprint (S)... KKR & Co. (KKR). DECREASED STAKES: Kinder Morgan (KMI). LIQUIDATED STAKES: General Motors (GM)... Williams (WMB).
News For EBAY;GM;DG;ACT;ADT;APC;CZR;WMB;KKR;KMI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
May 11, 2015
10:44 EDTGMGM ignition fund approves claims for 100 deaths, Detroit News says
Subscribe for More Information
09:21 EDTACTOn The Fly: Pre-market Movers
Subscribe for More Information
09:00 EDTACTActavis says committed to utilizing FCF to accelerate debt repayment
Subscribe for More Information
08:57 EDTACTActavis says 'doing exceptionally well' on cost synergy capture
Subscribe for More Information
08:52 EDTACTActavis sets 'aspirational' FY17 EPS target of $25
Subscribe for More Information
08:48 EDTACTActavis sees sNDA submission for low dosage Linzess in 2016
Subscribe for More Information
08:21 EDTKMIMitsubishi UFJ to hold a tour
Energy Tour travels throughout Houston and San Antonio, Texas to meet with various energy companies on May 11.
06:40 EDTACTActavis sees Eluxadoline, Cariprazine PDUFAs in Q2
Subscribe for More Information
06:37 EDTACTActavis sees 2015 EPS $17.00-$18.50, consensus $17.70
Sees 2015 pro forma revenue $22M-$22.5B, consensus $21.47B. Sees 2015 total net revenue $20.5B-$21B.
06:35 EDTACTActavis reports Q1 EPS $4.30, consensus $3.94
Reports Q1 revenue $4.23B., consensus $4.03B. Reports adjusted EBITDA of $1.78B compared to $860M last year. Results include the contribution from Allergan businesses for the period following the close on March 17.
May 10, 2015
19:25 EDTACTCourt rejects claim that drugmakers misled opiate patients, Bloomberg says
Subscribe for More Information
May 8, 2015
14:58 EDTADTADT Corp. to host analyst and investor day
Subscribe for More Information
14:36 EDTWMBWilliams to host analyst day
Subscribe for More Information
13:11 EDTACTEarnings Watch: Actavis to report quarterly results after Allergan acquisition
Actavis (ACT) is scheduled to report first quarter earnings before the market open on Monday, May 11 with a conference call scheduled for 8:00 am ET. Actavis, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic, branded generic, branded, biosimilar, and over-the-counter pharmaceutical products. EXPECTATIONS: Analysts are looking for earnings per share of $3.94 on revenue of $4.04B, according to First Call. The consensus range for EPS is $3.81-$4.06 on revenue of $3.79B-$4.22B. LAST QUARTER: Actavis reported fourth quarter EPS of $3.91, compared to consensus estimates of $3.67, on revenue of $4.01B against estimates of $3.84B. Actavis CEO Brent Saunders commented on the quarter: "In our North American Brands business, six of our top ten brand products saw double-digit growth, including our strongest performers Namenda franchise, Linzess, Estrace Cream, Teflaro and Bystolic. In our North American Generics business, strong results were driven by continued performance of our generic versions of Lidoderm and Concerta, and fourth quarter launches of generic versions of Intuniv and Celebrex. We continue to invest in expanding our brand and generic portfolios, with nine new product and line extension launches planned in 2015, and industry-leading expansion of our generic pipeline, with 44 Abbreviated New Drug Applications submitted in 2014." NEWS: On March 17, Actavis announced that it had completed the acquisition of Allergan (AGN) in a cash and equity transaction valued at approximately $70.5B. The combination creates one of the world’s top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23B anticipated in 2015. STREET RESEARCH: On April 8, Leerink analyst Jason Gerberry raised his price target for Actavis shares by $20 to $348 to account for the closing of the Allergan acquisition. Gerberry said he thinks the deal will result in higher overall company gross margins in 2015. He raised his revenue and earnings estimates for Actavis ahead of the company's Q1 results and reiterated an Outperform rating on the stock. PRICE ACTION: Actavis shares are up almost 3% since the company's last earnings report on February 18, and are trading up 2.4% in midday trading ahead of Monday's earnings release.
13:09 EDTEBAYCiti says 'sell in May, go away' on Twitter, LinkedIn, Zillow
Subscribe for More Information
10:01 EDTACTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:03 EDTGMBofA/Merrill auto analysts hold an analyst/industry conference call
Subscribe for More Information
08:47 EDTACTLeerink's specialty pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals/Generics Analyst Gerberry discuss the future of dry eye treatment and the data and outlook for pipeline agents Shire's Lifitegrast and Eleven Biotherapeutics' EBI-005 and expectations for Actavis' Restasis use, assuming future approval of one or more pipeline agents, on an Analyst/Industry conference call to be held on May 12 at 10:30 am.
06:22 EDTEBAYCitigroup sees internet stocks underperforming this summer
Citigroup analyst Mark May says that even with the recent share pullbacks, the broader internet index has still meaningfully outperformed broader indices year-to-date. The group is nearing peak valuations, which could lead to underperformance through the summer, May tells investors today in a research note. He recommends avoiding shares of Twitter (TWTR), LinkedIn (LNKD) and Zillow Group (Z), as the companies are going through business transitions. The analyst believes Amazon.com (AMZN), eBay (EBAY), Yelp (YELP), Netflix (NFLX), GrubHub (GRUB) and Facebook (FB) have company specific factors that should enable them to outperform the internet group over the near term.
06:13 EDTACTActavis initiated with a Buy at Mizuho
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use